Abiopharma

INDAPTUS THERAPEUTICS, INC. (INDP)

Symbol	INDP
Name	INDAPTUS THERAPEUTICS, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	THREE COLUMBUS CIRCLE,15TH FLOOR, NEW YORK, New York, 10019, United States
Telephone	646) 427-2727
Fax	—
Email	—
Website	https://www.indaptusrx.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001857044
Description	Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Additional info from NASDAQ: Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

2026-08-13 11:03

Indaptus Therapeutics INDP Notification

2026-08-13 11:00

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

2026-07-20 07:02

New Form EFFECT - Indaptus Therapeutics, Inc. Filed: 2026-07-17 AccNo: 9999999995-26-002348 Size: 1 KB

2026-07-16 17:36

New Form DEF 14A - Indaptus Therapeutics, Inc. Filed: 2026-07-16 AccNo: 0001493152-26-033545 Size: 3 MB

2026-06-26 22:40

New Form SCHEDULE 13D/A - Indaptus Therapeutics, Inc. Filed: 2026-06-26 AccNo: 0001829126-26-006953 Size: 20 KB

2026-06-26 21:01

New Form SCHEDULE 13D/A - Indaptus Therapeutics, Inc. Filed: 2026-06-26 AccNo: 0001829126-26-006951 Size: 10 KB

2026-06-26 21:00

New Form SCHEDULE 13D/A - Indaptus Therapeutics, Inc. Filed: 2026-06-26 AccNo: 0001829126-26-006950 Size: 11 KB

2026-06-26 21:00

New Form SCHEDULE 13D/A - Indaptus Therapeutics, Inc. Filed: 2026-06-26 AccNo: 0001829126-26-006949 Size: 11 KB

2026-06-26 18:22

New Form S-3 - Indaptus Therapeutics, Inc. Filed: 2026-06-26 AccNo: 0001493152-26-030346 Size: 554 KB

2026-06-22 18:25

New Form PRE 14A - Indaptus Therapeutics, Inc. Filed: 2026-06-22 AccNo: 0001493152-26-029633 Size: 3 MB

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT05651022	Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid T…	Phase1	Solid Tumor, Adult	Active_Not_Recruiting	2023-02-28	2027-09-30	ClinicalTrials.gov

Total clinical trials: 1

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Tislelizumab	Other	Phase PHASE1	Solid Tumor, Adult	ACTIVE_NOT_RECRUITING	NCT05651022
Decoy20	Other	Phase PHASE1	Solid Tumor, Adult	ACTIVE_NOT_RECRUITING	NCT05651022
Tislelizumab	DRUG	Phase PHASE1	Solid Tumor, Adult	ACTIVE_NOT_RECRUITING	NCT05651022
Decoy20	DRUG	Phase PHASE1	Solid Tumor, Adult	ACTIVE_NOT_RECRUITING	NCT05651022

Total products: 4